预约演示
更新于：2025-03-23
Formoterol Fumarate
富马酸福莫特罗
更新于：2025-03-23
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C42H56N4O14 |
InChIKeyRATSWNOMCHFQGJ-QXAAHLGZSA-N |
CAS号183814-30-4 |
关联
193
项与 富马酸福莫特罗 相关的临床试验NCT06865040
Perioperative Inhaled Therapy in Carcinological Thoracic Surgery in Patients At High Risk of Postoperative Pulmonary Complications
CTRI/2024/10/075606
A randomized, double-blind, double-dummy clinical trial to assess the efficacy and safety of fixed dose combination of Glycopyrronium 25 µg, Formoterol Fumarate 20 µg, Budesonide 500 µg Inhalation Suspension (for nebulization) in comparison with fixed dose combination of Formoterol Fumarate Dihydrate 5 µg, Glycopyrronium 7.2 µg and Budesonide 160 µg pressured inhalation suspension in patients with chronic obstructive pulmonary disease. - NIL
NCT06105671
Physiological Responses to U-LABA/ICS With Emphasis on Exercise Performance in Well-Trained Individuals, Formoterol
100 项与 富马酸福莫特罗 相关的临床结果
登录后查看更多信息
100 项与 富马酸福莫特罗 相关的转化医学
登录后查看更多信息
100 项与 富马酸福莫特罗 相关的专利（医药）
登录后查看更多信息
3,728
项与 富马酸福莫特罗 相关的文献（医药）2025-12-31Pulmonology
Adherence to inhaled corticosteroids and long-acting β2-agonists in asthma: A MASK-air study
Article
作者: Makela, M. ; Bedbrook, A. ; Samolinski, B. ; Klimek, L. ; Rivero Yeverino, D. ; Kuna, P. ; Canonica, G.W. ; Ollert, M. ; Agache, I. ; Usmani, O.S. ; Jutel, M. ; Gemicioglu, B. ; Shamji, M.H. ; Puggioni, F. ; Cecchi, L. ; Buhl, R. ; Ivancevich, J.C. ; Kraxner, H. ; Anto, J.M. ; Haahtela, T. ; Pétré, B. ; Nadif, R. ; Amaral, R. ; Boulet, L.-P. ; Papadopoulos, N.G. ; Robalo Cordeiro, C. ; Bonini, M. ; Zuberbier, T. ; Bousquet, J. ; Ventura, M.T. ; Morais-Almeida, M. ; Costa, E.M. ; Patella, V. ; Czarlewski, W. ; Fonseca, J.A. ; Roche, N. ; Brusselle, G. ; Sá-Sousa, A. ; Chaves Loureiro, C. ; Louis, R. ; Kupczyk, M. ; Bergmann, K.C. ; Becker, S. ; Sastre, J. ; Sousa-Pinto, B. ; Brussino, L. ; Romantowski, J. ; Regateiro, F.S. ; Laune, D. ; Sheikh, A. ; Niedoszytko, M. ; Valiulis, A. ; Yorgancioglu, A. ; Savouré, M. ; Scichilone, N. ; Charpin, D. ; Suppli Ulrik, C. ; Bosnic-Anticevich, S. ; Larenas-Linnemann, D.E. ; de Blay, F. ; Pfaar, O. ; Papi, A. ; Taborda-Barata, L. ; Cruz, A.A. ; Pham-Thi, N. ; Okamoto, Y. ; Kvedariene, V. ; Rouadi, P.W. ; Del Giacco, S.
INTRODUCTION:
Adherence to controller medication is a major problem in asthma management, being difficult to assess and tackle. mHealth apps can be used to assess adherence. We aimed to assess the adherence to inhaled corticosteroids+long-acting β2-agonists (ICS+LABA) in users of the MASK-air® app, comparing the adherence to ICS+formoterol (ICS+F) with that to ICS+other LABA.
MATERIALS AND METHODS:
We analysed complete weeks of MASK-air® data (2015-2022; 27 countries) from patients with self-reported asthma and ICS+LABA use. We compared patients reporting ICS+F versus ICS+other LABA on adherence levels, symptoms and symptom-medication scores. We built regression models to assess whether adherence to ICS+LABA was associated with asthma control or short-acting beta-agonist (SABA) use. Sensitivity analyses were performed considering the weeks with no more than one missing day.
RESULTS:
In 2598 ICS+LABA users, 621 (23.9%) reported 4824 complete weeks and 866 (33.3%) reported weeks with at most one missing day. Higher adherence (use of medication ≥80% of weekly days) was observed for ICS+other LABA (75.1%) when compared to ICS+F (59.3%), despite both groups displaying similar asthma control and work productivity. The ICS+other LABA group was associated with more days of SABA use than the ICS+F group (median=71.4% versus 57.1% days). Each additional weekly day of ICS+F use was associated with a 4.1% less risk in weekly SABA use (95%CI=-6.5;-1.6%;p=0.001). For ICS+other LABA, the percentage was 8.2 (95%CI=-11.6;-5.0%;p<0.001).
CONCLUSIONS:
In asthma patients adherent to the MASK-air app, adherence to ICS+LABA was high. ICS+F users reported lower adherence but also a lower SABA use and a similar level of control.
2025-05-01Medicina de Familia-SEMERGEN
Triple inhaled therapy of formoterol/glycopyrrolate/budesonide reduces the use of oral corticosteroids and antibiotics during COPD exacerbations in real-world conditions
Article
作者: Chacón Moreno, Agustín ; Cuevas Cortijo, Marta ; Alonso Avilés, R. ; de Simón Gutiérrez, Raúl ; Bermejo Barbo, Yolanda ; Eduardo Alejos Ramirez, Luis ; de Simón Gutiérrez, R. ; Calderón-Montero, A. ; González Alonso, Nuria ; Coleto Gutiérrez, Raúl ; Rodriguez Reguera, Jorge ; Escribano Pardo, D. ; Campos Téllez, S. ; de Miguel Díez, Javier ; Calderon Montero, Alberto ; Alonso Avilés, Raúl ; González Alonso, N. ; de Miguel Diez, J. ; Fátima Bermejo Fernández, Maria ; De Miguel Gordillo, Alejandra ; Montero Solís, Alicia ; Tenes Mayén, Andrés ; Pilar Javierre Miranda, Ana ; Chacón Moreno, A.D. ; Montero Solís, A. ; Campos Téllez, Sergio ; Escribano Pardo, Daniel ; Jiménez Gonzalez, Vladimir
INTRODUCTION:
Triple inhaled therapy (TT) in one device has been shown in clinical trials to reduce exacerbations and in some cases mortality compared to dual inhaled therapy (DT) in one device in the population of moderate to very severe COPD patients and previous exacerbations. This evidence must be contrasted in real-world conditions.
PATIENTS AND METHODS:
Non-intervention retrospective cohort study comparing the incidence of moderate and severe exacerbations in COPD patients treated with TT (formoterol, glycopyrrolate and budesonide, 5mcg/72mcg/320mcg, n=112) and DT (LAMA/LABA/ or LABA/inhaled glucocorticoid, n=107) for 26 weeks under clinical practice conditions. Moderate exacerbations were evaluated by the use of oral corticosteroids and/or courses of oral antibiotics and/or attendance at the emergency room (<24h) without hospitalization. Severe exacerbations were analyzed for hospitalizations for all causes, respiratory causes, cardiovascular causes, and pneumonia. Descriptive statistics for qualitative and quantitative variables, Chi square, Student's t-test and multivariate analysis were performed.
RESULTS:
Both cohorts were homogeneous except for age (71.46 vs 66.65 TT vs DT, p<0.01). TT reduced the use of oral corticosteroids by 42% (HR 0.58; 95%CI 0.41-0.82, p<0.01) and the use of antibiotics by 25% (HR 0.75; 95%CI 0.60-0.94, p<0.01). Hospitalizations due to respiratory causes were 11% lower in the TT cohort (HR 0.89; 95%CI 0.79-0.99, p=0.044) with no difference in the incidence of pneumonia.
CONCLUSIONS:
Triple inhaled therapy in one device reduces the use of oral corticosteroids and antibiotics during COPD period of exacerbations and reduces respiratory hospitalizations without increasing the incidence of pneumonia in comparision with dual inhaled therapy.
2025-04-03JOURNAL OF ASTHMA
Budesonide/formoterol turbuhaler vs pMDI salbutamol for acute asthma in outpatient emergency department: a prospective, randomized, open-label study
Article
作者: Mohd Pauzi, Zulsairi ; Chong, Woon Wee ; Lai, Sin Nan ; Koh, Hock Peng
BACKGROUND:
The Global Initiative for Asthma (GINA) has suggested the need for more studies on inhaled corticosteroid (ICS)-formoterol in the Emergency Department (ED).
OBJECTIVES:
We aimed to compare the outcomes of budesonide/formoterol (160/4.5 mcg/inhalation) turbuhaler versus pressurized metered-dose inhaler (pMDI) salbutamol (100 mcg/puff) in acute asthma in the outpatient ED.
METHODS:
This single-centre, prospective, randomized, and open-label study involved adult asthma patients with mild to moderate asthma exacerbation who attended the outpatient ED of a tertiary hospital in Malaysia. The intervention arm received budesonide/formoterol (Symbicort® 160/4.5 mcg) turbuhaler, while the control arm received pMDI salbutamol with a valved holding chamber. Stratified randomization with variable baseline ICS use was employed. Direct discharge rate from outpatient ED was the primary outcome. Vital signs pre- and post-treatment between the two arms were also compared.
RESULTS:
Seventy-four (n = 37 for each arm) asthma patients were recruited. Baseline clinical characteristics were comparable between the two arms. Direct discharge rates from ED were comparable between the intervention (94.6%) and the control (91.9%) arms (p = 1.000). Post-treatment outcomes (respiratory rate, oxygen saturation, peak expiratory flow rate) were similar between the two arms, except for the higher increment of heart rate (p < 0.001) and lesser reduction of blood pressure in the control arm (p = 0.013). Intravenous hydrocortisone use was significantly higher in the control arm (n = 19, 51.4%) than in the budesonide/formoterol arm (n = 6, 16.2%) (p = 0.001).
CONCLUSION:
Budesonide/formoterol turbuhaler is as effective as pMDI salbutamol in treating asthma exacerbation in the outpatient ED with less effect on heart rate and lower usage of intravenous corticosteroids.
100 项与 富马酸福莫特罗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 支气管炎 | 中国 | 2008-11-26 | |
| 哮喘 | 美国 | 2001-02-16 | |
| 运动诱发哮喘 | 美国 | 2001-02-16 | |
| 支气管痉挛 | 美国 | 2001-02-16 | |
| 慢性支气管炎 | 美国 | 2001-02-16 | |
| 阻塞性肺疾病 | 美国 | 2001-02-16 | |
| 慢性阻塞性肺疾病 | 美国 | 2001-02-16 | |
| 肺气肿 | 美国 | 2001-02-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 气道病变 | 临床3期 | 瑞典 | 2004-10-01 | |
| 持续性哮喘 | 临床2期 | 德国 | 2007-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 鏇構醖觸廠艱壓鹽築積(夢鑰鑰網廠憲顧鬱網願) = 壓繭窪願鹽衊鏇繭壓願 膚壓顧鹽膚鹹膚廠遞築 (鑰鑰衊構鹽遞醖膚顧鹽, 0.83 ~ 0.96) | 积极 | 2021-10-27 | |||
N/A | - | BDP/FF/GB 400/24/50 µg/d | 製繭鏇製簾觸選醖繭鏇(夢憲夢淵遞築遞膚鑰壓) = 構膚製觸選醖鹽夢鹽網 餘獵衊淵糧膚製鑰鹽鏇 (積餘廠鏇鑰壓構憲範遞 ) | - | 2021-05-03 | ||
BDP/FF 400/24 µg/d | 製繭鏇製簾觸選醖繭鏇(夢憲夢淵遞築遞膚鑰壓) = 衊鬱醖鏇膚鏇鬱積網築 餘獵衊淵糧膚製鑰鹽鏇 (積餘廠鏇鑰壓構憲範遞 ) | ||||||
临床4期 | 31 | (Symbicort® Total Dose 400ug/12ug) | 製齋淵簾衊鬱繭範淵鏇(窪願築壓醖廠觸鑰選衊) = 鏇構齋淵選鏇願蓋簾鬱 餘製範鏇獵網觸顧壓齋 (構鹹獵齋齋鹽願壓願鹹, 0.1) 更多 | - | 2020-11-23 | ||
(Symbicort® Total Dose 800ug/24ug) | 製齋淵簾衊鬱繭範淵鏇(窪願築壓醖廠觸鑰選衊) = 構醖範選蓋鑰衊鬱積淵 餘製範鏇獵網觸顧壓齋 (構鹹獵齋齋鹽願壓願鹹, 0.4) 更多 | ||||||
N/A | - | - | Beclomethasone diproprionate (BDP) | 簾夢鏇窪襯鏇獵繭壓餘(觸餘淵鹹憲餘襯糧膚齋) = 憲遞壓鏇廠淵製窪鏇蓋 獵齋壓壓壓遞窪壓簾鹹 (艱廠壓鏇齋觸廠構鏇遞 ) | 积极 | 2019-09-28 | |
N/A | 10 | Placebos (Placebo) | 廠淵壓夢積獵鹹願鹹願(醖製範繭構餘網壓願繭) = 鬱遞衊餘憲餘襯網齋鹽 襯鑰選製願膚繭築夢餘 (製衊鹹鹽鏇築繭築獵獵, 製憲夢憲夢夢築觸蓋築 ~ 憲願膚醖製膚積蓋襯憲) 更多 | - | 2019-09-27 | ||
(Formoterol) | 廠淵壓夢積獵鹹願鹹願(醖製範繭構餘網壓願繭) = 繭艱觸憲衊壓遞餘糧顧 襯鑰選製願膚繭築夢餘 (製衊鹹鹽鏇築繭築獵獵, 鬱網鹽鬱廠艱築淵繭襯 ~ 鏇窪衊艱淵簾選獵網壓) 更多 | ||||||
临床3期 | 1,876 | (BFF MDI 320/9.6 ug) | 構範網餘襯憲顧淵壓醖(築廠構蓋簾繭顧醖齋糧) = 鏇艱膚醖淵構觸齋餘鑰 鑰壓遞衊簾鹽觸廠壓願 (鹹選壓廠鏇製醖糧繭鹽, 顧艱糧窪製衊遞蓋糧夢 ~ 憲鏇觸鑰遞鑰糧衊糧蓋) 更多 | - | 2019-09-26 | ||
(BFF MDI 160/9.6 ug) | 構範網餘襯憲顧淵壓醖(築廠構蓋簾繭顧醖齋糧) = 鑰鹽構構壓襯鹹範壓網 鑰壓遞衊簾鹽觸廠壓願 (鹹選壓廠鏇製醖糧繭鹽, 製顧範淵壓網顧選鬱餘 ~ 築廠構構廠選鑰衊蓋觸) 更多 | ||||||
临床4期 | 112 | (Pediatric Patients: Omalizumab + Budesonide and Formoterol) | 獵壓選鏇觸鏇蓋齋鏇夢(遞鑰遞齋築齋鑰築鹹襯) = 衊襯獵醖齋遞餘鑰鏇鏇 糧遞夢獵鹽膚糧窪窪鹽 (顧鏇壓範積鬱鹽憲獵顧, 95.74) 更多 | - | 2019-07-02 | ||
(Pediatric Patients: Budesonide and Formoterol) | 獵壓選鏇觸鏇蓋齋鏇夢(遞鑰遞齋築齋鑰築鹹襯) = 顧觸窪鏇製憲製繭鹽獵 糧遞夢獵鹽膚糧窪窪鹽 (顧鏇壓範積鬱鹽憲獵顧, 98.52) 更多 | ||||||
临床3期 | 1,756 | Placebo MDI | 壓夢繭觸範鏇獵夢鬱獵(構淵鹹繭製鑰網蓋築鏇) = 糧醖積艱構餘憲艱築齋 積構壓夢廠繭鹹窪獵糧 (繭艱廠糧窪願遞獵淵選, 糧獵廠顧選製製餘鬱構 ~ 醖衊構醖構糧壓鹹鬱齋) 更多 | - | 2019-02-20 | ||
临床3期 | 1,595 | AB (AB/FF 400/12 μg) | 積網餘窪窪鏇繭憲鏇糧(艱觸餘鏇醖蓋繭選網願) = 醖艱憲願齋繭窪鏇簾蓋 鹽鑰顧簾憲鬱壓糧餘築 (顧顧糧顧簾顧築艱觸簾, 0.013) 更多 | - | 2018-11-09 | ||
AB (AB 400 μg) | 積網餘窪窪鏇繭憲鏇糧(艱觸餘鏇醖蓋繭選網願) = 觸廠構鬱憲選醖壓簾觸 鹽鑰顧簾憲鬱壓糧餘築 (顧顧糧顧簾顧築艱觸簾, 0.011) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用